These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 32040243)

  • 1. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis.
    Cheung CKM; Law MF; Chao DC; Wong SH; Ho R; Chao ACW; Lai JWY; Chan TYT; Tam MTK; Lau SLF; Tam THC
    J Dig Dis; 2020 Mar; 21(3):160-169. PubMed ID: 32040243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.
    Paul S; Dickstein A; Saxena A; Terrin N; Viveiros K; Balk EM; Wong JB
    Hepatology; 2017 Aug; 66(2):379-388. PubMed ID: 28128861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1111-1119. PubMed ID: 29845351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan.
    Chen CY; Tien FM; Cheng A; Huang SY; Chou WC; Yao M; Tang JL; Tien HF; Sheng WH
    BMC Gastroenterol; 2018 Jan; 18(1):6. PubMed ID: 29310589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.
    Paul S; Saxena A; Terrin N; Viveiros K; Balk EM; Wong JB
    Ann Intern Med; 2016 Jan; 164(1):30-40. PubMed ID: 26595058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
    Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
    J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.
    Sarmati L; Andreoni M; Antonelli G; Arcese W; Bruno R; Coppola N; Gaeta GB; Galli M; Girmenia C; Mikulska M; Pane F; Perno CF; Picardi M; Puoti M; Rambaldi A; Svicher V; Taliani G; Gentile G
    Clin Microbiol Infect; 2017 Dec; 23(12):935-940. PubMed ID: 28668466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.
    Mak JWY; Law AWH; Law KWT; Ho R; Cheung CKM; Law MF
    World J Gastroenterol; 2023 Sep; 29(33):4942-4961. PubMed ID: 37731995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.
    Zappulo E; Nicolini LA; Di Grazia C; Dominietto A; Lamparelli T; Gualandi F; Caligiuri P; Bruzzone B; Angelucci E; Viscoli C; Mikulska M
    Infection; 2019 Feb; 47(1):59-65. PubMed ID: 30232604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
    Kusumoto S; Arcaini L; Hong X; Jin J; Kim WS; Kwong YL; Peters MG; Tanaka Y; Zelenetz AD; Kuriki H; Fingerle-Rowson G; Nielsen T; Ueda E; Piper-Lepoutre H; Sellam G; Tobinai K
    Blood; 2019 Jan; 133(2):137-146. PubMed ID: 30341058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
    Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.
    Li P; Zhou L; Ye S; Zhang W; Wang J; Tang X; Liu J; Xu Y; Qian W; Liang A
    Front Immunol; 2021; 12():638678. PubMed ID: 34335561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
    Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH
    Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.
    Wu YT; Li X; Liu ZL; Xu Z; Dai W; Zhang K; Wu JS; Arshad B; Wu KN; Kong LQ
    PLoS One; 2017; 12(6):e0179680. PubMed ID: 28640902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.
    Jiang XW; Ye JZ; Li YT; Li LJ
    World J Gastroenterol; 2018 Jul; 24(28):3181-3191. PubMed ID: 30065564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
    Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
    J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.